[1]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,(20):49-53.[doi:10.3969/j.issn.1006-1959.2018.20.015]
 TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,(20):49-53.[doi:10.3969/j.issn.1006-1959.2018.20.015]
点击复制

二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年20期
页码:
49-53
栏目:
论著
出版日期:
2018-10-15

文章信息/Info

Title:
Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC
文章编号:
1006-1959(2018)20-0049-05
作者:
田春琴12赵新汉1蒋冬梅2崔立春2党升强2杜建飞2
1.西安交通大学第一附属医院肿瘤科,陕西 西安 710061;2.国际合作长安医院肿瘤科,陕西 西安 710016
Author(s):
TIAN Chun-qin12ZHAO Xin-han1JIANG Dong-mei2CUI Li-chun2DANG Sheng-qiang2DU Jian-fei2
1.Department of Oncology,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,Shaanxi,China;2.Department of Oncology,Chang'an Hospital,International Cooperation,Xi'an 710016,Shaanxi,China
关键词:
表皮生长因子受体酪氨酸激酶抑制剂非小细胞肺癌Meta分析
Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerMeta-analysis
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.20.015
文献标志码:
A
摘要:
目的 系统评价二线应用表皮生长因子受体酪氨酸激酶抑制剂与化疗比较治疗非选择型非小细胞肺癌患者的疗效。方法 自2008年1月~2014年12月对Pubmed、Cochrane library、EMBASE中检索相关的主题词及自由词,收集EGFR-TKIs与化疗相比二线治疗非选择型NSCLC的疗效的随机对照研究。按纳入标准及排除标准筛选文献,采用cochrane偏倚风险评估表对纳入文献进行质量评价,自纳入文献中提取有效数据,应用RevMan 5.3.5和STATA 12.0分析并对比非选择型NSCLC患者在EGFR-TKIs治疗中的疗效。敏感性分析和发表偏倚分析以评价结果的稳定性和可靠性。结果 共纳入5篇RCT,共2741例患者,Meta 分析显示:对于非选择型晚期NSCLC患者:二线EGFR-TKIs治疗的PFS(HR=0.98;95CI%:0.85~1.13;P=0.75)、OS(HR=1.01;95CI%:0.95~1.07;P=0.78)、ORR(RR=1.63;95CI%:0.93~2.86;P=0.09)与化疗相比无明显差异。结论 与化疗对比,作为二线用药的EGFR-TKIs应用于非选择型晚期NSCLC患者,不能起到有效的治疗作用。
Abstract:
Objective To evaluate the efficacy of second-line application of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of patients with non-selective non-small cell lung cancer.Methods From January 2008 to December 2014,the related keywords and free words were searched for Pubmed,Cochrane library,and EMBASE.A randomized controlled trial comparing the efficacy of EGFR-TKIs with chemotherapy for second-line treatment of non-selective NSCLC was performed.The literature was selected according to the inclusion criteria and exclusion criteria.The quality of the included literature was evaluated using the cochrane bias risk assessment form.Effective data were extracted from the literature.RevMan 5.3.5 and STATA 12.0 were used to analyze and compare the efficacy of non-selective NSCLC patients in the treatment of EGFR-TKIs.Sensitivity analysis and publication bias analysis to assess the stability and reliability of the results.Results A total of 5 RCTs were included in a total of 2 741 patients. Meta-analysis showed:for non-selective advanced NSCLC patients:PFS for second-line EGFR-TKIs(HR=0.98;95CI%:0.85-1.13;P=0.75),OS(HR=1.01;95CI%:0.95-1.07;P=0.78),ORR(RR=1.63;95CI%:0.93-2.86;P=0.09)showed no significant difference compared with chemotherapy.Conclusion Compared with chemotherapy,EGFR-TKIs used as second-line drugs are not effective in the treatment of patients with non-selective advanced NSCLC.

参考文献/References:

[1]Rizvi NA,Rusch V,Pao W,et al.Molecular characteristics predict clinical outcomes:prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene[J].Clin Cancer Res,2011,17(10):3500-3506. [2]Kris MG,Johnson BE,Berry LD,et al.Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs[J].Jama,2014,311(19):1998-2006. [3]Maruyama R,Nishiwaki Y,Tamura T,et al.Phase III study, V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer[J].J Clin Oncol,2008,26(26):4244-4252. [4]Lee DH,Park K,Kim JH,et al.Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy[J].Clinical Cancer Research,2010,16(4):1307-1314. [5]Kim ES, Hirsh V, Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase III trial[J].Lancet,2008,372 (9652):1809-1818. [6]Kelly K,Azzoli CG,Zatloukal P,et al.Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer(NSCLC)after failure of prior platinum-based therapy[J].Journal of Thoracic Oncology,2012,7(6):1041-1048. [7]Ciuleanu T,Stelmakh L,Cicenas S,et al.Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced,non-small-cell lung cancer with poor prognosis(TITAN):a randomised multicentre,open-label,phase 3 study[J].Lancet Oncology,2012,13(3):300-308. [8]Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].New England Journal of Medicine,2010,362(25):2380. [9]Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or caboplatin-paclitaxel in non-small cell lung cancer[J].N Engl J Med,2009,361(10):947-957. [10]Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,12(8):735. [11]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomised phase 3 trial[J].Lancet Oncology,2014,15(2):213-222. [12]Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncology,2012,13(3):239-246. [13]Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncology,2010,11(2):121-128. [14]Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker Analyses and Final Overall Survival Results From a Phase Ⅲ,Randomized,Open-Label,First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia(IPASS)[J].Journal of Clinical Oncology,2011,29(21):2866-2874. [15]Zhou C.Overall survival(OS)results from OPTIMAL (CTONG0802),a phase III trial of erlotinib(E)versus carboplatin plus gemcitabine(GC)as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer(NSCLC)[J].Journal of Clinical Oncology,2012,30(15_suppl). [16]Yun CH,Boggon TJ,Li Y,et al.Structures of lung cancer-derived EGFR mutants and inhibitor complexes:mechanism of activation and insights into differential inhibitor sensitivity[J].Cancer Cell,2007,11(3):217-227. [17]Chiu CH,Yang CT,Shih JY,et al.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations[J].Journal of Thoracic Oncology,2015,10(5):793-799. [18]孟苗.埃克替尼治疗晚期非小细胞肺癌的疗效观察[J].中国实用医药,2016,11(20):166-167. [19]Mitsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncology,2010,11(2):121-128. [20]Pazares L,Soulières D,Moecks J,et al.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC[J].Journal of Cellular&Molecular Medicine,2014,18(8):1519-1539. [21]Gridelli C,Ciardiello F,Feld R,et al.International multicenter randomized phaseⅢstudy of first-line erlotinib(E)followed by second-line cisplatin plus gemcitabine(CG)versus first-line CG followed by second-line E in advanced non-small cell lung cancer(aNSCLC):The TORCH trial.[J].Journal of Clinical Oncology,2010,28(15):7508. [22]Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase III trial[J].Lancet,2008,372(9652):1809.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
 TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,(20):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
 TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,(20):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
 LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,(20):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
 YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,(20):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]

更新日期/Last Update: 2018-11-09